Testing CS1 CAR-T for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have tried at least 3 different treatments for your myeloma, including a proteasome inhibitor (like bortezomib), an anti-CD38 drug (like daratumumab), and a BCMA-directed therapy.
- Your cancer can be measured by lab tests (like M-protein in blood or urine) or by a biopsy showing myeloma cells.
- You are at least 18 years old and able to carry out your daily activities without needing a lot of help.
- Your kidneys, liver, lungs, and heart are working well enough based on standard tests.
- You are not pregnant or breastfeeding, and you agree to use effective contraception for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This study tests a new treatment called CT103A CAR-T therapy for people newly diagnosed with high-risk multiple myeloma. It uses your own immune cells to attack the cancer cells, and may help control the disease even when it's aggressive.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.